Search

Your search keyword '"Serna, Javier"' showing total 739 results

Search Constraints

Start Over You searched for: Author "Serna, Javier" Remove constraint Author: "Serna, Javier"
739 results on '"Serna, Javier"'

Search Results

51. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

52. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

53. Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

55. Towards a Comprehensive View of Accretion, Inner Disks, and Extinction in Classical T Tauri Stars: An ODYSSEUS Study of the Orion OB1b Association

57. CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study

58. CLL-573 Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

59. CLL-186 Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia

60. Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

61. Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia

62. Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study

63. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

64. 1127-P: Diabetes Risk in Marginalized Urban Settings in Mexico City

65. Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.

66. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome

67. The Seventeenth Data Release of the Sloan Digital Sky Surveys : Complete Release of MaNGA, MaStar, and APOGEE-2 Data

68. The ODYSSEUS Survey. Motivation and First Results: Accretion, Ejection, and Disk Irradiation of CVSO 109

69. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

71. Stellar multiplicity and stellar rotation: insights from APOGEE

73. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

77. The ODYSSEUS Survey. Motivation and First Results: Accretion, Ejection, and Disk Irradiation of CVSO 109

78. Stellar Rotation of T Tauri Stars in the Orion Star-forming Complex

79. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

80. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

81. Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

82. Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

83. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

84. Double-lined Spectroscopic Binaries in the APOGEE DR16 and DR17 Data

85. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

86. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

87. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

88. Understanding the Angular Momentum Evolution of T Tauri and Herbig Ae/Be Stars

90. Accretion in the PDS 70 system

91. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

92. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

93. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

94. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

95. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

98. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

99. Time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): first presentation of 4-year data from the MURANO study

100. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Catalog

Books, media, physical & digital resources